« Return to News | Drug Sponsors

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

Friday, May 4, 2012 08:00 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Sanofi Pasteur’s, standalone Inactivated Poliovirus Vaccine (IPV) against acute flaccid poliomyelitis (Imovax Polio). Imovax Polio will be added to the country's public immunization program on September 1.

Since 1988, start of the Global Polio Eradication Initiative led by the World Health Organization (WHO) and its partners, the number of polio cases has been reduced by 99% worldwide.  The approval of Imovax Polio by Japanese health authorities is another step towards a polio-free world. Imovax Polio is an inactivated poliovirus vaccine made from poliovirus types 1, 2 and 3. Since its launch in France in 1982, Imovax Polio has been approved in 86 countries. Sanofi Pasteur has supplied more than 800 million doses of standalone IPV and IPV-containing combination vaccines worldwide to date.

"Inactivated poliovirus vaccine is the standard of care for polio vaccination in polio-free countries. Sanofi Pasteur is committed to doing its utmost to contribute to protecting as many infants as possible in Japan from polio," said Olivier Charmeil, president and CEO of Sanofi Pasteur.

In the past, Japan had immunized its population with Oral Poliovirus Vaccine (OPV), starting in 1961.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.